Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alcon Inc. (ALC.SW)
Geneva, CH
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.24% | +0.52% | -18.51% | -17.57% | -20.04% | -20.87% | -36.52% | -29.56% | -18.80% | +0.56% | +0.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 17 | 0 |
| Hold | 5 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+9.9% ★ Q1'26: +7.0% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+1.0% Q1'26: -47.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+13.7% Q1'26: +10.3% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+13.1% Q1'26: +15.5% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+4.6% Q1'26: +5.0% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.3% ★ Q1'26: -1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×2.04× Q1'26: 3.20× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 22 Rev. Ana. 16 EPS Ana. |
Dec 2027 22 Rev. Ana. 20 EPS Ana. |
Dec 2028 15 Rev. Ana. 13 EPS Ana. |
Dec 2029 11 Rev. Ana. 11 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.28B
est: 7.15B (+1.8%)
|
7.51B
est: 7.27B (+3.3%)
|
6.83B
est: 6.07B (+12.6%)
|
8.29B
est: 7.54B (+10.0%)
|
8.72B
est: 8.10B (+7.7%)
|
9.46B
est: 10.75B (-12.1%)
|
9.91B
est: 9.76B (+1.5%)
|
10.90B
est: 10.26B (+6.2%)
|
10.78B
10.67B – 11.06B
+5.0% YoY
|
11.44B
11.25B – 11.74B
+6.1% YoY
|
12.15B
11.99B – 12.47B
+6.2% YoY
|
12.87B
12.70B – 13.20B
+5.9% YoY
|
13.77B
13.58B – 14.12B
+7.0% YoY
|
| EBITDA |
1.35B
est: 1.54B (-12.7%)
|
1.21B
est: 1.57B (-23.1%)
|
1.11B
est: 868.97M (+28.0%)
|
1.76B
est: 1.00B (+75.4%)
|
1.72B
est: 1.05B (+64.0%)
|
2.24B
est: 2.52B (-11.0%)
|
2.68B
est: 2.29B (+17.1%)
|
2.78B
est: 2.40B (+15.5%)
|
2.52B
2.50B – 2.59B
+5.0% YoY
|
2.68B
2.64B – 2.75B
+6.1% YoY
|
2.85B
2.81B – 2.92B
+6.2% YoY
|
3.01B
2.97B – 3.09B
+5.9% YoY
|
3.22B
3.18B – 3.31B
+7.0% YoY
|
| EBIT |
-276.00M
est: 446.88M (-161.8%)
|
-219.00M
est: 454.48M (-148.2%)
|
-511.00M
est: -172.54M (-196.2%)
|
538.00M
est: -198.89M (+370.5%)
|
597.00M
est: -208.20M (+386.7%)
|
1.02B
est: 1.11B (-8.4%)
|
1.45B
est: 1.01B (+43.2%)
|
1.42B
est: 1.06B (+33.9%)
|
1.12B
1.11B – 1.15B
+5.0% YoY
|
1.19B
1.17B – 1.22B
+6.1% YoY
|
1.26B
1.24B – 1.29B
+6.2% YoY
|
1.33B
1.32B – 1.37B
+5.9% YoY
|
1.43B
1.41B – 1.46B
+7.0% YoY
|
| Net Income |
-315.00M
est: 1.07B (-129.6%)
|
-656.00M
est: 941.96M (-169.6%)
|
-531.00M
est: -586.47M (+9.5%)
|
376.00M
est: -676.02M (+155.6%)
|
335.00M
est: 362.00M (-7.5%)
|
974.00M
est: 1.23B (-20.8%)
|
1.02B
est: 1.50B (-32.0%)
|
1.03B
est: 1.53B (-33.0%)
|
1.40B
1.25B – 1.96B
-8.4% YoY
|
1.77B
1.70B – 1.96B
+26.4% YoY
|
2.07B
1.42B – 2.66B
+16.7% YoY
|
2.48B
2.44B – 2.57B
+19.9% YoY
|
2.84B
2.79B – 2.93B
+14.2% YoY
|
| SGA |
2.80B
est: 2.55B (+9.8%)
|
2.85B
est: 2.59B (+9.8%)
|
2.69B
est: 2.50B (+7.5%)
|
3.08B
est: 2.89B (+6.5%)
|
3.07B
est: 3.02B (+1.5%)
|
3.21B
est: 3.70B (-13.4%)
|
3.25B
est: 3.75B (-13.2%)
|
3.61B
est: 3.53B (+2.2%)
|
3.71B
3.68B – 3.81B
+5.0% YoY
|
3.94B
3.88B – 4.04B
+6.1% YoY
|
4.19B
4.13B – 4.29B
+6.2% YoY
|
4.43B
4.37B – 4.55B
+5.9% YoY
|
4.74B
4.68B – 4.86B
+7.0% YoY
|
| EPS |
-0.65
est: 2.14 (-130.3%)
|
-1.34
est: 1.89 (-170.8%)
|
-1.09
est: 1.06 (-203.0%)
|
0.77
est: 2.11 (-63.5%)
|
0.68
est: 2.27 (-70.0%)
|
1.98
est: 2.49 (-20.5%)
|
2.06
est: 2.99 (-31.2%)
|
2.08
est: 3.06 (-32.1%)
|
3.36
2.53 – 3.95
+9.7% YoY
|
3.84
3.42 – 3.96
+14.3% YoY
|
4.34
2.86 – 5.35
+13.1% YoY
|
5.00
4.92 – 5.17
+15.2% YoY
|
5.72
5.62 – 5.91
+14.2% YoY
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-07 | Wells Fargo | Overweight | Overweight | Maintain |
| 2026-05-06 | BTIG | Buy | Buy | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers SLI UCITS ETF 1D DXS0.DE | 2.81% | 16.54M | 0.25% |
| 2 | iShares SLI UCITS ETF (DE) EXI1.DE | 2.78% | 18.16M | 0.51% |
| 3 | iShares SLI ETF (CH) CSSLI.SW | 2.77% | 25.38M | 0.35% |
| 4 | Global X - Aging Population ETF AGNG | 2.29% | 1.96M | 0.50% |
| 5 | Invesco STOXX Europe 600 Optimised Health Care UCITS ETF SC0T.DE | 2.26% | 306.3K | 0.20% |
| 6 | Amundi MSCI Europe Ex EMU ESG Selection UCITS ETF Acc CU9.PA | 2.16% | 5.75M | 0.30% |
| 7 | Amundi DJ Switzerland Titans 30 UCITS ETF Dist C030.DE | 2.04% | 5.14M | 0.25% |
| 8 | iShares MSCI Switzerland ETF EWL | 1.91% | 40.55M | 0.50% |
| 9 | iShares SMI ETF (CH) CSSMI.SW | 1.84% | 59.17M | 0.35% |
| 10 | Franklin FTSE Switzerland ETF FLSW | 1.84% | 1.51M | 0.09% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David J. Endicott | Chief Executive Officer & Director | 3M | male |
| Franck Leveiller | SVP of Global Research & Development and Chief Scientific Officer | — | — |
| Ian Bell | Senior Vice President & Chief Operating Officer | — | male |
| Kimberly Martin | Senior VP and Chief HR & Corporate Communications | — | female |
| Laurent Attias | Senior VP of Corporate Strategy, Business Development and Licensing (BD&L), M&A | — | male |
| Leon Sergio Duplan Fraustro | Senior Vice President & President of Americas | — | male |
| Margaret Buckley | Chief Accounting Officer | — | — |
| Muru Murugappan | Senior Vice President and Chief Information & Transformation Officer | — | male |
| Royce R. Bedward | Senior Vice President, General Counsel & Corporate Secretary | — | male |
| Timothy C. Stonesifer | Senior Vice President & Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALC.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
